UNH · 10-Q · 2026Q1 · Full report

Liquidity and Cash Position

UNITEDHEALTH GROUP INC · 2026-05-05 · Importance 37 · Surprise 6

As of March 31, 2026, UnitedHealth reported total cash, cash equivalents, available-for-sale debt securities and marketable equity securities of $80.0 billion, comprising approximately $28.0 billion of cash and cash equivalents (of which $1.1 billion was available for general corporate use), $50.1 billion of debt securities and $1.9 billion of marketable equity securities. The company also reported $10.3 billion of loan receivables and a debt securities portfolio with a weighted-average duration of 4.1 years and weighted-average credit rating of Double A. UnitedHealth states it believes its capital resources are sufficient to meet future short- and long-term liquidity needs and that given the significant portion of the portfolio held in cash and equivalents it does not anticipate fair value fluctuations materially impacting liquidity or capital position. The company continues to access capital markets as needed and has pending acquisition commitments (~$3.0 billion anticipated capital, expected to close mostly in H2 2026).

Key facts

• As of March 31, 2026, cash, cash equivalents, available-for-sale debt securities and marketable equity securities balances totaled $80.0 billion, including approximately $28.0 billion of cash and cash equivalents, $50.1 billion of debt securities and $1.9 billion of investments in marketable equity securities. source
• The company has entered into agreements to acquire companies in the health care sector expected to close in the second half of 2026, with total anticipated capital required of approximately $3.0 billion. source
• The available-for-sale debt securities portfolio had a weighted-average duration of 4.1 years and a weighted-average credit rating of “Double A” as of March 31, 2026. source
• Of the $28.0 billion of cash and cash equivalents as of March 31, 2026, $1.1 billion was available for general corporate use. source
• The company had $10.3 billion of loan receivables as of March 31, 2026. source
• Increase in cash and cash equivalents, including cash within businesses held for sale, was $3,466 million for the three months ended March 31, 2026 compared to $5,496 million for the three months ended March 31, 2025 (a decrease of $2,030 million). source
• Net increase in cash and cash equivalents was $3,636 million for the three months ended March 31, 2026 compared to $5,405 million for the three months ended March 31, 2025 (a decrease of $1,769 million). source
• As of March 31, 2026, the Board had authorization to purchase up to 19.3 million shares of the company's common stock under the share repurchase program. source